An estimated 20–25% of the population is affected by chronic, non-communicable
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …

Abstract Dipeptidyl peptidase 4 (DPP4) inhibitors (DPP4is) are oral anti-diabetic drugs
(OADs) for the treatment of type 2 diabetes mellitus (T2DM) through inhibiting the …

Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease
provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and …

Bullous pemphigoid is an autoimmune subepithelial disease characterised by pruritus
followed by urticarial plaques and finally bullae on the skin and mucosa. Drug-associated …

Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering skin disease
that mainly affects the elderly. Typical clinical features include the widespread blisters, often …

Importance Recent studies suggest that dipeptidyl peptidase 4 (DPP-4) inhibitors are
associated with an increased risk of developing bullous pemphigoid (BP). Population-based …

Importance The association between the use of medications and the development of bullous
pemphigoid (BP) is unclear. Objective To assess the associations between previous …

Dipeptidyl-peptidase IV (DPP4), originally identified as an aminopeptidase in 1960s, is an
ubiquitously expressed protease presented as either a membrane-bound or soluble form …

Dipeptidyl peptidase-4 inhibitors have been suspected to induce bullous pemphigoid (BP).
The objective of this study was to compare the observed frequency of gliptin intake in a large …

Autoimmune bullous skin disorders are rare but meaningful chronic inflammatory diseases,
many of which had a poor or devastating prognosis prior to the advent of …